 BERKELEY, Calif. and VANCOUVER, British Columbia, June 07, 2021 GLOBE NEWSWIRE -- BriaCell Therapeutics Corp. NASDAQ: BCTX, BCTXWTSX-V:BCT the Company or BriaCell, a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has closed its previously announced private placement of i 4,370,343 common shares at a purchase price of US5.26, ii 800,000 pre-funded common share purchase warrants at a purchase price of US5.25 exercisable at any time after the date of issuance at an exercise price of US0.01 per common share and iii 5,170,343 warrants to purchase up to 5,170,343 common shares, which resulted in gross proceeds to BriaCell of US27.2 million, before deducting offering expenses the Offering. The Company expects to use the net proceeds of the private placement to further advance its research and development pipeline and for general corporate purposes. 